Overview

Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD

Status:
Completed
Trial end date:
2021-12-21
Target enrollment:
0
Participant gender:
All
Summary
The changes in liver function, body mass index, controlled attenuation parameters, liver stiffness and HBV-DNA at different time points in each group before and after treatment were counted to explore the clinical efficacy of Ganshuang granules combined with tenofovir in the treatment of CHB complicated with NAFLD.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sichuan Leshan Traditional Chinese Medicine Hospital
Criteria
Inclusion Criteria:

Chronic hepatitis B patients not treated with antiviral drugs; Fatty liver was diagnosed by
B-ultrasound and imaging; No history of excessive drinking; Good drug compliance and
regular medication; Exclusion Criteria: Non chronic hepatitis B patients; Taking other
drugs; liver failure, liver cancer and other diseases; patients who refused to sign
informed consent;